Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics) Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...

Depression Drugs Global Market Report 2022: Emergence of Novel Techniques for the Development of Antidepressants With Minimal Side-Effects Presents Opportunities Dublin, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...

Major Depressive Disorder Market Report 2022-2032: Insight, Epidemiology and Market Forecasts - Emerging Drugs, Pipeline Activities, Therapies, Drugs Uptake Dublin, June 23, 2022 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder - Market Insight, Epidemiology And Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's...

Global Depression Drugs Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts Dublin, June 25, 2021 (GLOBE NEWSWIRE) -- The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...

Depressive Disorder Market 2019-2025: Global Insights on Growth Trends, Expansion Plans, Key Players, Types, Applications and Regional Analysis: Orbis Research Dallas, Texas, June 25, 2019 (GLOBE NEWSWIRE) -- Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated...